[Statins and ASS for primary prevention of cardiovascular and cerebrovascular disease].
Whereas statins and acetylsalicylic acid (ASA) are considered gold standard for secondary prevention following myocardial infarction or atherotrombotic stroke, there are inconsistent data on the use of these drugs for primary prevention in patients with increased cardiovascular risk. Some meta-analyses indicated that the use of statins and ASA for primary prevention of cardiovascular disease can reduce the risk of cardiovascular events such as ischemic stroke or myocardial infarction. However, the effects of primary prevention with statins and ASA on mortality varied in the data included in these meta-analyses. Therefore the guidelines of the German College of General Practitioners and Family Physicians recommend primary prevention with statins and ASA only in those patients who have a 10-year risk of cardiovascular events which exceeds 20 %. Divergently, primary prevention with ASA is not recommended by the European Society of Cardiology. Observational studies suggested that treatment success of primary prevention with statins and ASA depends on various factors such as adherence to medication and prescription behavior of physicians. This review summarizes the current literature on primary prevention of cardiovascular events with ASA and statins.
Institut für Klinische Pharmakologie und.
L
L
Goltz
Klinik und Poliklinik für Neurologie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden.
U
U
Bodechtel
Klinik und Poliklinik für Neurologie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden.
T
T
Siepmann
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage*; D002316:Cardiotonic Agents / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D011322:Primary Prevention / Q000379:methods*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002316:Cardiotonic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin